Elevance Health's growth engine has decelerated materially, with revenue growth falling from 14.8% in 2025Q1 to just 1.4% in 2026Q3, suggesting the favorable hard-market pricing cycle that supported prior earnings is fading.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth decelerated to 1.4% by 2026Q3 while the combined ratio rose to 95.8% from 93.1% in 2024Q2, reflecting a loss ratio that climbed to 84.4% and steadily eroding underwriting margin.
Elevance Health has delivered a trailing‑12‑month EPS growth of 36.29%, placing it in the top 25% of its industry. This momentum underpins expectations for continued earnings expansion.
The company reports a return on equity of 12.90% and a gross profit margin of 100%, both ranking in the top 10% of its sector. These figures signal efficient capital use and high pricing power.
Elevance has increased its dividend for 15 straight years, yielding 2.42% today. The long‑term dividend track record supports a stable income stream for investors.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 21, 2026 | $6.99+48.4% vs $4.71 | $50.4B+2.4% vs $49.3B |
Q3 2026 Jul 15, 2026 | $7.45+20.0% vs $6.21 | $49.8B+1.9% vs $48.9B |
Q2 2026 Apr 22, 2026 | $12.58+16.3% vs $10.82 | $49.5B+2.7% vs $48.2B |
Q1 2026 Jan 28, 2026 | $3.33+7.4% vs $3.10 | $49.3B-1.1% vs $49.8B |
Wall Street is punishing CVS Health (NYSE:CVS | CVS Price Prediction) for a plan to break up the pharmacy, benefits and insurance empire it spent years building, even after a strong quarter. CVS stock is at $80.
Does Elevance Health (ELV) have what it takes to be a top stock pick for momentum investors? Let's find out.
On October 27, 2026, we delve into the DCF analysis for Elevance Health Inc (ELV), a company that has shown notable price performance over the past year, with a
Citizens Financial Group Inc. RI increased its position in shares of Elevance Health, Inc. (NYSE: ELV) by 77.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,604 shares of the company's stock after purchasing an additional 2,873 shares
Benchmark ELV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Elevance Health Inc. (ELV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $425.62 | $92.3B | 16.94 | 12.62% | 2.84% | 13.25% | 1.62% | |
| $394.15 | $357.95B | 29.79 | 11.81% | 3.53% | 15.18% | 2.21% | |
| $83.85 | $106.99B | 60.32 | 7.85% | 1.18% | 6.41% | 3.19% | |
| $293.59 | $77.66B | 13.24 | 11.26% | 2.27% | 15.16% | 2.06% | |
| $433.74 | $52.08B | 44.08 | 10.06% | 0.88% | 6.89% | 0.82% | |
| $69.70 | $34.43B | -5.12 | 19.44% | 0.75% | 6.76% | — |
Elevance Health Inc. (ELV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Elevance Health Inc. (ELV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 21, 2026·SEC
Jul 15, 2026·SEC
Jun 10, 2026·SEC
Get notified when ELV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Elevance Health Inc. (ELV) stock FAQ — growth, dividends, profitability & financials explained
Elevance Health Inc. (ELV) grew revenue by 12.6% in fiscal year 2025, compared with the prior fiscal year.
Yes. Elevance Health Inc. (ELV) earned $5.14B in net income over the trailing twelve months (a 2.5% net margin).
Yes. Elevance Health Inc. (ELV) pays a dividend that yields 1.62% at the current price, a moderate yield.
Elevance Health Inc. (ELV) had a return on equity (ROE) of 13.3% in fiscal year 2025. That is in line with the market's typical 10-15%.
Elevance Health Inc. (ELV) has a combined ratio of 95.9%. A ratio below 100% indicates underwriting profitability.
